Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Moderna

Thumbnail
February 25, 2021

Vaccine developers move to stay ahead of Covid-19 variants

Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.

Thumbnail
February 23, 2021

The Covid-19 valuation derby

Article image
Vantage logo
February 18, 2021

How low can you go in Covid-19 vaccine trials?

Article image
Vantage logo
February 03, 2021

Astrazeneca looks to US data and a next-gen vaccine

Article image
Vantage logo
February 02, 2021

Sputnik V fails to come in from the cold

The Russian-made vaccine posts competitive phase III data – but not on the easily stored formulation.

Article image
Vantage logo
February 02, 2021

Pfizer sees $15bn of 2021 Covid sales; could it do $30bn?

Article image
Vantage logo
January 29, 2021

Novavax and J&J join the Covid-19 vaccine push

Relief as two further pandemic vaccines succeed, but the data confirm variants to be a problem.

Article image
Vantage logo
January 26, 2021

J&J tight-lipped ahead of next week's Covid-19 vaccine data

Article image
Vantage logo
January 25, 2021

Merck’s Covid-19 vaccines head for the scrapheap

Merck & Co’s move illustrates how hard it will be for the second wave of Covid-19 vaccine candidates to succeed.

Article image
Vantage logo
January 21, 2021

Biopharma’s stock market winners and losers in 2020

Article image
Vantage logo
January 20, 2021

2020 drug approvals rise despite Covid-19

Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.